Tools for Enabling Process Analytical Technology Applications in Biotechnology - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Tools for Enabling Process Analytical Technology Applications in Biotechnology
The success of process analytical technology (PAT), a recent initiative by FDA, depends to a large extent on efficient control of manufacturing processes to achieve predefined quality of the final product. In this paper, the authors review the various analytical methods that can enable use of PAT.


Pharmaceutical Technology
pp. s16-s22, s28-s31

27. K. Hipkins, Pharm. Tech. Eur. 2, 157–163 (2007).

28. C. Justice et al., Biotechnol. Adv. 29, 391–401 (2011).

29. A. Sharma, and S.G. Schulman, Wiley InterScience 2, 172–176 (1999).

30. S. Marose, C. Lindemann, and T. Scheper, Biotech. Progress 14, 63–74, (1998).

31. P. Ana Teixeira et al., Wiley InterScience 102, 1108–1116 (2008).

32. P. Ana Teixeira, M. Tiago Duarte, M.J.T. Carrondo, and M. Paula Alves, Biotechnol.Bioeng. 102, 1852–1861 (2011).

33. M. Reinecke and T. Scheper, J. Biotechnol. 17, 145–53 (1997).

34. A.S. Rathore, L. Parr, S. Dermawan, K. Lawson, and Y. Lu, Biotechnol. Prog. 26, 448–57 (2010).

35. A.S. Rathore, R. Wood, A. Sharma, and S. Dermawan, Biotechnol. Bioeng. 101, 1366–1374 (2008).

36. A.S. Rathore, A. Sharma, and D. Chilin, BioPharm Int. 19, 48–57 (2006).

37. M. Tina Larson et al., Biotech. and Bioengin. 77, 553–563 (2002).

38. R.L. Fahrner et al., J. Chromatogr. A. 827, 37–43 (1998).

39. J. Barackman, I.Prado, C. Karunatilake, and K. Furuya, J. Chromatogr. A. 16, 57–64 (2004).

40. C. Bittner, G. Wehnert, and T. Scheper, Biotechnol. Bioeng. 60, 24–35 (1998).

41. V. Camisard et al., Biotechnol. Bioeng. 78, 73–80 (2002).

42. J.S. Guez et al., J. Biotechnol. 111, 335–343 (2004).

43. G. Rudolph et al., Biotechnol. Bioeng. 99, 136–145 (2008).

44. N. Wei et al., Biotechnol. Lett. 29, 373–378 (2007).

45. A. Prediger et al., Chem. Engin. & Tech. 34, 837–840 (2011).

46. C. Buschmüller et al., Eur. J. Pharm. Biopharm. 69, 380–387 (2008).

47. http://www.nature.com/naturephotonics/.

48. M.P. Wagh, Y.H. Sonawane, and O.U. Joshi., Indian J. Pharm. Sci. 71, 235–241 (2009).

49. H. Wu, E.J. Heilweil, A.S, Hussain, and M.A. Khan, J. Pharm. Sci. 97, 970–984 (2008).

50. T. Schmid, Anal. Bioanal. Chem. 384, 1071–1086 (2006).

51. V. Deepak Bageshwar, S. Avinash Pawar, V. Vineeta Khanvilkar, and J. Vilasrao Kadam, Eurasian J. Anal. Chem. 5, 187–203 (2010).

52. T. Schmid et al., Environ. Sci. Technol. 36, 4135–4141 (2002).

53. http://pharma.metrohm.com/pdfdownload/Prosp_Pharma_Analytik_e_web.pdf.

54. W. Chew and P. Sharratt, Anal. Methods 2, 1412–1438 (2010).

55. P. Werle, R. Mücke, and F. Slemr, App. Phys. B: Lasers and Optics 57, 131–139 (1993).

56. S. Armenta, S. Garrigues, M. Gauradia, and P. Rondeau, Anal. Chem. Acta. 545, 99–106 (2005).

57. A.S. Rathore, R. Bhambure, and V. Ghare, Bioanal. Chem. 398, 137–154 (2010).

*This article was previously published in the January 2012 issue of LCGC North America.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
33%
Breakthrough designations
11%
Protecting the supply chain
39%
Expedited reviews of drug submissions
11%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here